Switch theme
Sign up to access all valuation multiples
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, as well as its antibody platform CANxx.
2009
22
LTM Revenue $5.2M
LTM EBITDA -$16.8M
$26.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cantargia has a last 12-month revenue (LTM) of $5.2M and a last 12-month EBITDA of -$16.8M.
In the most recent fiscal year, Cantargia achieved revenue of n/a and an EBITDA of -$16.7M.
Cantargia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cantargia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$16.8M | XXX | -$16.7M | XXX | XXX | XXX |
| EBITDA Margin | -324% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$15.3M | XXX | -$17.8M | XXX | XXX | XXX |
| EBIT Margin | -294% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$16.5M | XXX | -$17.1M | XXX | XXX | XXX |
| Net Margin | -319% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Cantargia's stock price is SEK 1 (or $0).
Cantargia has current market cap of SEK 350M (or $37.0M), and EV of SEK 246M (or $26.0M).
See Cantargia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.0M | $37.0M | XXX | XXX | XXX | XXX | $-0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Cantargia has market cap of $37.0M and EV of $26.0M.
Cantargia's trades at n/a EV/Revenue multiple, and -1.6x EV/EBITDA.
Equity research analysts estimate Cantargia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cantargia has a P/E ratio of -2.2x.
See valuation multiples for Cantargia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $37.0M | XXX | $37.0M | XXX | XXX | XXX |
| EV (current) | $26.0M | XXX | $26.0M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -1.6x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.2x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | -1.3x | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCantargia's last 12 month revenue growth is 114%
Cantargia's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
Cantargia's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cantargia's rule of X is -40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cantargia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 114% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -324% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cantargia acquired XXX companies to date.
Last acquisition by Cantargia was XXXXXXXX, XXXXX XXXXX XXXXXX . Cantargia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cantargia founded? | Cantargia was founded in 2009. |
| Where is Cantargia headquartered? | Cantargia is headquartered in Sweden. |
| How many employees does Cantargia have? | As of today, Cantargia has 22 employees. |
| Who is the CEO of Cantargia? | Cantargia's CEO is Mr. Damian Marron. |
| Is Cantargia publicy listed? | Yes, Cantargia is a public company listed on STO. |
| What is the stock symbol of Cantargia? | Cantargia trades under CANTA ticker. |
| When did Cantargia go public? | Cantargia went public in 2015. |
| Who are competitors of Cantargia? | Similar companies to Cantargia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cantargia? | Cantargia's current market cap is $37.0M |
| What is the current revenue of Cantargia? | Cantargia's last 12 months revenue is $5.2M. |
| What is the current revenue growth of Cantargia? | Cantargia revenue growth (NTM/LTM) is 114%. |
| What is the current EV/Revenue multiple of Cantargia? | Current revenue multiple of Cantargia is 5.0x. |
| Is Cantargia profitable? | Yes, Cantargia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cantargia? | Cantargia's last 12 months EBITDA is -$16.8M. |
| What is Cantargia's EBITDA margin? | Cantargia's last 12 months EBITDA margin is -324%. |
| What is the current EV/EBITDA multiple of Cantargia? | Current EBITDA multiple of Cantargia is -1.5x. |
| What is the current FCF of Cantargia? | Cantargia's last 12 months FCF is -$20.6M. |
| What is Cantargia's FCF margin? | Cantargia's last 12 months FCF margin is -397%. |
| What is the current EV/FCF multiple of Cantargia? | Current FCF multiple of Cantargia is -1.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
